CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponseBreast CancerQuarfloxin,PidnarulexXu et al., 2017
CALKAlternative Transcript (ATI)PredictiveSupportsSensitivity/ResponseSkin MelanomaCrizotinibWiesner et al., 2015
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerSchell et al., 2016
CVHLExon 1-3 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
DGNAQMutationPredictiveSupportsSensitivity/ResponseUveal MelanomaMirdametinib,Sotrastaurin AcetateChen et al., 2014
BNTRK1OverexpressionPrognosticSupportsBetter OutcomeNeuroblastomaNakagawara et al., 1993
CBTKT316APredictiveSupportsResistanceChronic Lymphocytic LeukemiaIbrutinibSharma et al., 2016
BGNASc.393T>CPrognosticSupportsPoor OutcomeBreast CarcinomaOtterbach et al., 2007
DKRASG13DPredictiveSupportsResistanceBreast CancerPictilisibO'Brien et al., 2010
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibLudovini et al., 2011
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
DPIK3CAK111NPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaTrametinibFlaherty et al., 2012
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaElisei et al., 2008
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibMiller et al., 2012
CEGFRL858R OR EGFR Exon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibYu et al., 2014
CEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinib,ErlotinibPao et al., 2005
DEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaLapatinibLi et al., 2008
DATMMutationPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
BKITExon 11 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
BEGFRWildtypePredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinibMok et al., 2009
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibDouillard et al., 2010
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
BTP53ALTERATIONPredictiveSupportsResistanceOvarian CancerCarboplatin,CisplatinReles et al., 2001
BTP53OverexpressionPredictiveSupportsSensitivity/ResponseStomach CancerCisplatin,Etoposide,MitomycinBataille et al., 2003
BGNASc.393T>CPrognosticSupportsPoor OutcomeBladder Urothelial CarcinomaFrey et al., 2005
BGNASc.393T>CPrognosticSupportsBetter OutcomeColorectal CancerFrey et al., 2005
BGNASc.393T>CPredictiveSupportsResistanceEsophageal CancerCisplatin,FluorouracilAlakus et al., 2009
BGNASc.393T>CPrognosticSupportsBetter OutcomeClear Cell Renal Cell CarcinomaFrey et al., 2006
BGNASc.393T>CPrognosticSupportsBetter OutcomeChronic Lymphocytic LeukemiaFrey et al., 2006
BGNASc.393T>CPrognosticSupportsPoor OutcomeMelanomaFrey et al., 2010
BRRM1UnderexpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCisplatin,GemcitabineNie et al., 2013
BRETC609YPredisposingSupportsPredispositionMedullary Thyroid CarcinomaCalva et al., 2009
CLMNA::NTRK1Fusion AND NTRK1 G595R AND NTRK1 G667CPredictiveSupportsResistanceColorectal AdenocarcinomaEntrectinibRusso et al., 2016
DTP53WildtypePredictiveSupportsSensitivity/ResponseCancerRebemadlinEfeyan et al., 2007
DTP53WildtypePredictiveSupportsSensitivity/ResponseCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Deleterious MutationPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Deleterious MutationPredictiveSupportsResistanceCancerRebemadlinEfeyan et al., 2007
BCTNNB1T41ADiagnosticSupportsPositiveDesmoid TumorLazar et al., 2008
BCTNNB1S45FDiagnosticSupportsPositiveDesmoid TumorLazar et al., 2008
DARID1ALossPredictiveSupportsSensitivity/ResponseOvarian Clear Cell CarcinomaGSK126Bitler et al., 2015
DCTNNB1Activating MutationPredictiveSupportsResistanceMelanomaAnti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal AntibodySpranger et al., 2015
BCD274ExpressionPredictiveSupportsResistanceHead And Neck Squamous Cell CarcinomaRadiation TherapySkinner et al., 2017
DMYCOverexpressionPredictiveSupportsSensitivity/ResponseLung Small Cell CarcinomaCisplatin,Prexasertib,OlaparibSen et al., 2017
DFLT3D835VPredictiveDoes Not SupportSensitivity/ResponseAcute Myeloid LeukemiaQuizartinibKampa-Schittenhelm et al., 2013
Page 14 of 96
PreviousNext